Summit Therapeutics Inc. Insider Trading

SMMT

⊜ Compare

Last 12 months

Insiders bought $104M on the open market and sold nothing.

Net open-market

+$104M

5 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

3 / 0

executives and directors

Last open-market buy

Jun 2026

Jun 12, 2026

Get an email when SMMT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 12	Mahkam Zanganeh Co-Chief Executive Officer	Bought	3,810,000	$13.12	$50M	0.6%	Form 4
Jun 12	Robert W Duggan Co-Chief Executive Officer	Bought	3,810,000	$13.12	$50M	0.6%	Form 4
Jun 4	Manmeet Singh Soni COO and CFO	Bought 2 parts	50,000	$14.45 average	722K	1.6%	Form 4
Jun 4	Mahkam Zanganeh Co-Chief Executive Officer	Bought	100,000	$14.60	$1.46M	<0.1%	Form 4
Jun 4	Robert W Duggan Co-Chief Executive Officer	Bought	100,000	$14.60	$1.46M	<0.1%	Form 4
Oct 21, 2025	Yu Xia Director	Bought	533,617	$18.74	$10M	1.7%	Form 4
Oct 21, 2025	Mahkam Zanganeh Co-Chief Executive Officer	Bought	26,680	$18.74	500K	<0.1%	Form 4
Oct 21, 2025	Robert W Duggan Co-Chief Executive Officer	Bought	26,680	$18.74	500K	<0.1%	Form 4
Sep 10, 2025 – Sep 11, 2025	Mahkam Zanganeh Co-Chief Executive Officer	Bought 2 parts	338,394	$17.69 average	$5.98M	<0.1%	Form 4
Sep 10, 2025 – Sep 11, 2025	Robert W Duggan Co-Chief Executive Officer	Bought 2 parts	338,394	$17.69 average	$5.98M	<0.1%	Form 4

Jun 12
Mahkam Zanganeh
Co-Chief Executive Officer · bought 3,810,000 at $13.12
$50M
0.6% of stake
Jun 12
Robert W Duggan
Co-Chief Executive Officer · bought 3,810,000 at $13.12
$50M
0.6% of stake
Jun 4
Manmeet Singh Soni
COO and CFO · bought 50,000 at avg $14.45
722K
1.6% of stake
Jun 4
Mahkam Zanganeh
Co-Chief Executive Officer · bought 100,000 at $14.60
$1.46M
<0.1% of stake
Jun 4
Robert W Duggan
Co-Chief Executive Officer · bought 100,000 at $14.60
$1.46M
<0.1% of stake
Oct 21, 2025
Yu Xia
Director · bought 533,617 at $18.74
$10M
1.7% of stake
Oct 21, 2025
Mahkam Zanganeh
Co-Chief Executive Officer · bought 26,680 at $18.74
500K
<0.1% of stake
Oct 21, 2025
Robert W Duggan
Co-Chief Executive Officer · bought 26,680 at $18.74
500K
<0.1% of stake
Sep 10, 2025 – Sep 11, 2025
Mahkam Zanganeh
Co-Chief Executive Officer · bought 338,394 at avg $17.69
$5.98M
<0.1% of stake
Sep 10, 2025 – Sep 11, 2025
Robert W Duggan
Co-Chief Executive Officer · bought 338,394 at avg $17.69
$5.98M
<0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SMMT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SMMT

CompareIntrinsic value

BMRNBiomarin Pharmaceutical Inc.

$58.51+1.77%51

BFRIBiofrontera Inc.

$0.87-6.34%30

BGMBGM Group Ltd.

$9.54-1.90%26

TGTXTG Therapeutics, Inc.

$61.18+5.34%57

RAREUltragenyx Pharmaceutical Inc.

$16.10-4.05%40

IDYAIdeaya Biosciences Inc.

$31.96-2.83%40

MIRMMirum Pharmaceuticals Inc.

$85.00-1.61%30

LEXXLexaria Bioscience Corp.

$3.49-7.43%10

Held by ETFs

SMMT is in 46 US ETFs. The largest of them, with SMMT's weight in each:

Spot a number that looks wrong? Check it in SMMT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SMMT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.